In December 2023, the U.S. Food and Drug Administration (FDA) issued nine Warning Letters for the manufacture and distribution of unapproved over-the-counter (OTC) antimicrobial animal drugs for use in aquarium fish and birds. The Warning Letters illustrate the continued efforts by the Center for Veterinary Medicine (CVM) to support the judicious use of antimicrobials in animals. The Warning Letters reflect FDA’s determination that unapproved animal drugs that are sold without a veterinarian’s prescription represent a significant risk for non-judicious use of medically important antimicrobials, even if these drugs are not intended for food-producing animals.
FDA’s Warning Letters were directed at firms manufacturing and distributing OTC animal drugs for use in aquarium fish and birds. The OTC drugs in question were not approved by FDA, nor listed on FDA's index for unapproved animal drugs for minor species. Importantly, FDA stated in all nine Warning Letters that the agency was “particularly concerned” about the public health risks of these unapproved products, given that they were sold without veterinary prescriptions while containing antimicrobials that were medically important in the treatment of human disease. The antimicrobials found in these drugs identified in the Warning Letters included[1]:
Each of these antimicrobials has been previously identified by FDA in draft guidance as a “medically important antimicrobial,” meaning these antimicrobials are important for treating human disease. For more than a decade, CVM has undertaken efforts to support the judicious use of antimicrobials in animals, with the aim of slowing antimicrobial resistance in humans by optimizing therapeutic efficacy and minimizing selection of resistant microorganisms. Notably, CVM announced a 5-year action plan in 2018 supporting antimicrobial stewardship in veterinary settings. This has resulted in some significant initiatives, such as CVM encouraging sponsors to voluntarily change their FDA-approved OTC animal drugs containing medically important antimicrobials to prescription status. The Warning Letters represent FDA’s effort to extend this initiative to unapproved drugs containing antimicrobials important for human health that are sold without veterinarian prescription oversight.
If you have any questions regarding FDA’s approval process for animal drugs or policies concerning medically important antimicrobials, please contact either of the authors of this alert or the Hogan Lovells attorney with whom you generally work.
Authored by David Horowitz and Bert Lao
[1] In addition to the drugs listed below, FDA’s December 14, 2023 News Release also identifies tetracycline among the animal drugs identified as important in human medicine.
FDA may permit Rx-to-OTC switch using additional conditions beyond traditional labeling
Modernization of U.S. cosmetics regulation will be phased in over time
FDA ups OTC monograph facility fees 45% for FY 2021, with exemption for some hand sanitizer makers
Inside the FDA Advanced Manufacturing Technologies Designation Program
Are you sure want to delete comment ?
Scan this QR Code to share this content
